Urothelial Cancers: Ureter, Renal Pelvis, and Bladder

Seminars in Oncology Nursing

Volumn 28, Issue 3, 2012, Pages 154-162

  Tyler, Allison ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

Chemotherapy; Psychosocial; Renal pelvis; Sexuality; Urothelial

Indexed keywords

ARTICLE; BLADDER TUMOR; HUMAN; KIDNEY PELVIS; KIDNEY TUMOR; METHODOLOGY; NURSING; ONCOLOGY NURSING; PATHOLOGY; TRANSITIONAL CELL CARCINOMA; URETER TUMOR; UROTHELIUM;

CARCINOMA, TRANSITIONAL CELL; HUMANS; KIDNEY NEOPLASMS; KIDNEY PELVIS; ONCOLOGIC NURSING; URETERAL NEOPLASMS; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 84864335407     PISSN: 07492081     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.soncn.2012.05.004     Document Type: Article

References (47)

1. American Cancer Society. Bladder cancer. Atlanta, GA; American Cancer Society. Available at: (accessed March 3, 2012). http://www.cancer.org/Cancer/BladderCancer/DetailedGuide/bladder-cancer-what-is-bladder-cancer.
2. Lima G., Jarrett T., Clarke N. Etiology and management of urothelial tumors of the renal pelvis and ureter. Textbook of bladder cancer 2006, 237-256. Taylor & Francis, United Kingdom. S.P. Lerner, M.P. Schoenberg, C.N. Sternberg (Eds.).
3. American Cancer Society. Bladder cancer statistics. Atlanta, GA; American Cancer Society. Available at: (accessed March 3, 2012). http://www.cancer.org.
4. Raghavan D., Tuthill K. The Cleveland Clinic guide to bladder cancer 2010, Kaplan, New York.
5. White R.W.D., Deitch A.D. Cytology and DNA ploidy. Textbook of bladder cancer 2006, 207-210. Taylor & Francis, United Kingdom. S.P. Lerner, M.P. Schoenberg, C.N. Sternberg (Eds.).
6. Morgan T.M., Clark P.E. Bladder cancer. Curr Opin Oncol 2010, 22:242-249.
7. Jewett H.S.G. Infiltrating carcinoma of the bladder. Relation of depth penetration of the bladder wall to incidence of local extension and metastases. J Urol 1946, 55:366-372.
8. American Joint Committee on Cancer. AJCC Cancer Staging Handbook 2010, 497-505. Springer, New York. Ed 7. S.B. Edge, D.R. Byrd, C.C. Compton, A.G. Fritz, F.L. Greene, A. Trotti (Eds.).
9. Yap S.A., Schupp C.W., Chamie K., et al. Effect of age on transitional cell carcinoma of the upper urinary tract: presentation, treatment, and outcomes. Urology 2011, 78:87-92.
10. National Cancer Institute. Transitional cell cancer of the renal pelvis and ureter treatment. Bethesda, MD; National Cancer Institute. Available at: (accessed October 2, 2011). http://www.cancer.gov/cancertopics/pdq/treatment/transitionalcell/HealthProfessional.
11. Raman J.D., Ng C.K., Scherr D.S., et al. Impact of tumor location on prognosis for patients with upper tract urothelial carcinoma managed by radical nephroureterectomy. Eur Urol 2010, 57:1072-1079.
12. Messing E.M., Catolona W. Urothelial tumours of the renal pelvis and ureter. Campbell's urology 2002, 2383-2410. Saunders, Philadelphia, PA. Ed 8. M.F. Campbell, P.C. Walsh, A.B. Retik (Eds.).
13. Malek R.S., Aguilo J.J., Hattery R.R. Radiolucent filling defects of the renal pelvis: classification and report of unusual cases. J Urol 1975, 114:508-513.
14. Murphy D.M., Zincke H., Furlow W.L. Management of high grade transitional cell cancer of the upper urinary tract. J Urol 1981, 125:25-29.
15. Dodd L.G., Johnston W.W., Roberson C.N., et al. Endoscopic brush cytology of the upper urinary tract. Evaluation of its efficacy and potential limitations in diagnosis. Acta Cytol 1997, 41:377-384.
16. Smith A.K., Stephenson A.J., Lane B.R., et al. Inadequacy of biopsy for diagnosis of upper tract urothelial carcinoma: implications for conservative management. Urology 2011, 78:82-86.
17. Hall M.C., Chang S.S., Dalbagni G., et al. Guideline for the management of nonmuscle invasive bladder cancer (stages Ta1, T1, and Tis): 2007 update. J Urol 2007, 178:2314-2330.
18. Hattori R., Yoshino Y., Gotoh M., et al. Laparoscopic nephroureterectomy for transitional cell carcinoma of renal pelvis and ureter: Nagoya experience. Urology 2006, 67:701-705.
19. Li W.M., Shen J.T., Li C.C., et al. Oncologic outcomes following three different approaches to the distal ureter and bladder cuff in nephroureterectomy for primary upper urinary tract urothelial carcinoma. Eur Urol 2010, 57:963-969.
20. Jeldres C., Lughezzani G., Sun M., et al. Segmental ureterectomy can safely be performed in patients with transitional cell carcinoma of the ureter. J Urol 2010, 183:1324-1329.
21. Sylvester R.J., van der Meijden A.P.M., Lamm D.L. Intravesical Bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 2002, 168:1964-1970.
22. Lamm D.L., Thor D.E., Harris S.C., et al. Bacillus Calmette-Guérin immunotherapy of superficial bladder cancer. J Urol 1980, 124:38-40.
23. Lamm D.L., Blumenstein B.A., Crissman J.D., et al. Maintenance Bacillus Calmette-Guérin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol 2000, 163:1124-1129.
24. Berry D.L., Blumenstein B.A., Magyary D.L., et al. Local toxicity patterns associated with intravesical Bacillus Calmette-Guérin: a Southwest Oncology Group Study. Int J Urol 1996, 3:98-100.
25. Au L.J., Badalament R.A., Wientjes M.G., et al. Methods to improve efficacy of intravesical Mitomycin C: results of a randomized phase III trial. J Natl Cancer Inst 2001, 93:597-604.
26. Lamm D.L., Riggs D.R., Traynelis C.L., et al. Apparent failure of current intravesical chemotherapy prophylaxis to influence the long-term course of superficial transitional cell carcinoma of the bladder. J Urol 1995, 153:1444-1450.
27. Thrasher J.V., Crawford E.D. Complications of intravesical chemotherapy. Urol Clin North Am 1992, 19:529-536.
28. Eastham J.A., Huffman J.L. Technique of mitomycin C instillation in the treatment of upper urinary tract urothelial tumors. J Urol 1993, 150(2 Pt 1):324-325.
29. Jabbour M.E., Smith A.D. Primary percutaneous approach to upper urinary tract transitional cell carcinoma. Urol Clin North Am 2000, 27:739-750.
30. Sternberg C.N. Current perspectives in muscle-invasive bladder cancer. Eur J Cancer 2002, 38:460-467.
31. Sternberg C.N. Neo-adjuvant chemotherapy in the treatment of muscle invasive bladder cancer. Textbook of bladder cancer 2006, 657-664. Taylor & Francis, United Kingdom. S.P. Lerner, M.P. Schoenberg, C.N. Sternberg (Eds.).
32. Harker W.G., Meyers F.J., Freiha F.S., et al. Cisplatin, methotrexate, and vinblastine: an effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract. A Northern California Oncology Group study. J Clin Oncol 1985, 3:1463-1470.
33. Yagoda A. The role of cisplatin-based chemotherapy in advanced urothelial tract cancer. Semin Oncol 1989, 16(suppl 6):98-104.
34. Mead G.M., Russell M., Clark P., et al. A randomized trial comparing methotrexate and vinblastine (MV) with cisplatin, methotrexate and vinblastine (CMV) in advanced transitional cell carcinoma: results and a report on prognostic factors in a Medical Research Council study. MRC Advanced Bladder Cancer Working Party. Br J Cancer 1998, 78:1067-1075.
35. Moore M.J., Tannock I.F., Ernst D.S., et al. Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer. J Clin Oncol 1997, 15:3441-3445.
36. Kaufman D., Raghavan D., Carducci M., et al. Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer. J Clin Oncol 2000, 18:1921-1927.
37. von der Maase H., Hansen S.W., Roberts J.T., et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000, 18:3068-3077.
38. Kattan J., Culine S., Theodore C., et al. Second-line MVAC therapy in patients previously treated with the MVAC regimen for metastatic urothelial cancer. Ann Oncol 1993, 4:793-794.
39. Lichtman S.M., Skirvin J.A., Venulapalli S. Pharmacology of antineoplastic agents in older cancer patients. Crit Rev Oncol Haematol 2003, 46:101-114.
40. Osoba D., Hsu M.A., Copley-Merriman C., et al. Stated preferences of patients with cancer for health-related quality-of-life (HRQOL) domains during treatment. Qual Life Res 2006, 15:273-283.
41. de Boer-Dennert M., de Wit R., Schmitz P.I.M., et al. Patient perceptions of the side-effects of chemotherapy: the influence of 5-HT3 antagonists. Br J Cancer 1997, 76:1055-1061.
42. Mansson A., Mansson W. When the bladder is gone: quality of life following different types of urinary diversion. World J Urol 1999, 17:211-218.
43. Mansoon A., Christensson P., Johnson G., et al. Can preoperative psychological defensive strategies and mood in bladder cancer patients and type of lower urinary tract reconstruction predict postcystectiomy psychological adjustment?. Br J Urol 1998, 82:348-356.
44. Beitz J.M., Zuzelo P.R. The lived experience of having a neobladder. Western J Nurs Res 2003, 25:294-316.
45. Silver L. The sexual rehabilitation of persons with cancer. Cancer Pract 2000, 8:10-15.
46. van der Aa M.N., Bekker M.D., van der Kwast T.H., et al. Sexual function of patients under surveillance for bladder cancer. BJU Int 2009, 104:35-40.
47. Urostomy and Continent Urinary Diversion. National Institute of Diabetes and Digestive and Kidney Diseases. Available at: (accessed December 17, 2011). http://kidney.niddk.nih.gov/kudiseases/pubs/urostomy/#urostomy.